80.47 USD
-1.47
1.79%
At close Oct 17, 4:00 PM EDT
After hours
80.47
+0.00
0.00%
1 day
-1.79%
5 days
0.14%
1 month
-1.87%
3 months
2.00%
6 months
7.41%
Year to date
11.05%
1 year
16.62%
5 years
63.06%
 

About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Employees: 6,990

0
Funds holding %
of 6,740 funds
0
Analysts bullish %
of 12 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 3 (+2) [Q2]

140% more call options, than puts

Call options by funds: $28.8M | Put options by funds: $12M

0.34% more ownership

Funds ownership: 95.03% [Q1] → 95.37% (+0.34%) [Q2]

0% less funds holding

Funds holding: 687 [Q1] → 686 (-1) [Q2]

1% less first-time investments, than exits

New positions opened: 71 | Existing positions closed: 72

5% less capital invested

Capital invested by funds: $17.4B [Q1] → $16.5B (-$864M) [Q2]

8% less repeat investments, than reductions

Existing positions increased: 246 | Existing positions reduced: 268

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$78
3%
downside
Avg. target
$87
8%
upside
High target
$95
18%
upside

12 analyst ratings

positive
58%
neutral
42%
negative
0%
Needham
Mike Matson
56% 1-year accuracy
64 / 115 met price target
12%upside
$90
Buy
Reiterated
15 Oct 2024
Leerink Partners
Puneet Souda
75% 1-year accuracy
3 / 4 met price target
12%upside
$90
Outperform
Maintained
8 Oct 2024
Mizuho
Anthony Petrone
68% 1-year accuracy
23 / 34 met price target
12%upside
$90
Outperform
Maintained
4 Oct 2024
Evercore ISI Group
Vijay Kumar
74% 1-year accuracy
28 / 38 met price target
2%upside
$82
In-Line
Maintained
1 Oct 2024
Citigroup
Patrick Donnelly
67% 1-year accuracy
16 / 24 met price target
6%upside
$85
Neutral
Downgraded
1 Oct 2024

Financial journalist opinion

Based on 16 articles about HOLX published over the past 30 days

Charts implemented using Lightweight Charts™